JP2019535017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535017A5 JP2019535017A5 JP2019518463A JP2019518463A JP2019535017A5 JP 2019535017 A5 JP2019535017 A5 JP 2019535017A5 JP 2019518463 A JP2019518463 A JP 2019518463A JP 2019518463 A JP2019518463 A JP 2019518463A JP 2019535017 A5 JP2019535017 A5 JP 2019535017A5
- Authority
- JP
- Japan
- Prior art keywords
- analysis
- gene
- detection
- sample
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (15)
- エピジェネティックリプログラミングのための標的の同定方法であって、
癌を有する対象由来のDNAを含有する試料中の大型組織化ヘテロクロマチンリジン(K)−9修飾ドメイン(LOCK)および大型DNA低メチル化ブロックを検出することを含む、方法。 - 前記試料は固形腫瘍由来である、請求項1に記載の方法。
- 前記対象は、PDACを有する、または、PDACおよび/もしくはその転移を有する危険性がある、請求項1に記載の方法。
- 前記検出は、H3K9Me2/3および/またはH4K20Me3の分析を含み、
任意に、前記検出は、H3K9Me2/3および/またはH4K20Me3に対する抗体についてのChIPによるものであり、任意にその後に配列決定が続く、請求項1に記載の方法。 - 前記検出は、H3K27Acおよび/またはH3K9Acの分析を含み、
任意に、前記検出は、H3K27Acおよび/またはH3K9Acに対する抗体についてのChIPによるものであり、任意にその後に配列決定が続く、請求項1に記載の方法。 - 前記検出は、ウエスタンブロッティングによる、請求項1に記載の方法。
- 前記検出は、全ゲノム亜硫酸水素塩配列決定によるものである、請求項1に記載の方法。
- 遺伝子発現分析をさらに含む、請求項2〜6のいずれか1つに記載の方法。
- 転移についてのドライバー変異が存在しない、請求項1〜8のいずれか1つに記載の方法。
- ユークロマチンアイランドおよび/またはユークロマチンLOCKの分析をさらに含む、請求項1〜9のいずれか1つに記載の方法。
- DNA試料中のユークロマチンドメイン(ECD)の変化を同定する方法であって、
治療計画の前後でのECDの分析を含み、治療計画に対する応答性の予後または分析を提供する、方法。 - DNA試料中のLOCKの変化を同定する方法であって、
治療計画の前後でのLOCKの分析を含み、治療計画に対する応答性の予後または分析を提供する、方法。 - 前記分析がコンビナトリアル法によるものである、請求項11または12に記載の方法。
- 原発腫瘍における転移傾向を同定するための、差次的に発現される遺伝子の使用であって、
該遺伝子は、本明細書の表中の遺伝子、酸化ストレス遺伝子、EMT遺伝子、免疫学的応答遺伝子、DNA修復遺伝子、グルコース代謝遺伝子、oxPPP遺伝子、およびPGD遺伝子から選択される、使用。 - oxPPPの阻害を含むエピゲノム変化に影響を与える作用物質または化合物を同定するための方法であって、
作用物質または化合物と接触させる前後に、請求項1に記載の対象由来の試料を分析し、エピゲノム変化に対する作用物質または化合物の効果を測定することを含む、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662405155P | 2016-10-06 | 2016-10-06 | |
US62/405,155 | 2016-10-06 | ||
PCT/US2017/055376 WO2018067840A1 (en) | 2016-10-06 | 2017-10-05 | Large-scale epigenomic reprogramming links anabolic glucose metabolism to distant metastasis during the evolution of pancreatic caner progression |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019535017A JP2019535017A (ja) | 2019-12-05 |
JP2019535017A5 true JP2019535017A5 (ja) | 2020-10-15 |
JP7239468B2 JP7239468B2 (ja) | 2023-03-14 |
Family
ID=61831296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019518463A Active JP7239468B2 (ja) | 2016-10-06 | 2017-10-05 | ラージスケールエピゲノムのリプログラミングは、膵癌進行の進展中の同化グルコース代謝を遠位転移に結びつける |
Country Status (5)
Country | Link |
---|---|
US (2) | US11795510B2 (ja) |
EP (1) | EP3522924A4 (ja) |
JP (1) | JP7239468B2 (ja) |
AU (1) | AU2017340743A1 (ja) |
WO (1) | WO2018067840A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115927608B (zh) * | 2022-01-28 | 2023-10-10 | 臻智达生物技术(上海)有限公司 | 用于预测胰腺癌发生风险的生物标志物、方法和诊断设备 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7153691B2 (en) | 2002-11-13 | 2006-12-26 | G6 Science Corp. | Method of identifying and assessing DNA euchromatin in biological cells for detecting disease, monitoring wellness, assessing bio-activity, and screening pharmacological agents |
WO2009058102A1 (en) * | 2007-11-02 | 2009-05-07 | Agency For Science, Technology And Research | Methods and compounds for preventing and treating a tumour |
EP2707506B1 (en) | 2011-05-12 | 2018-07-11 | The Johns Hopkins University | Method of detecting cancer through generalized loss of stability of epigenetic domains, and compositions thereof |
WO2013152186A1 (en) | 2012-04-04 | 2013-10-10 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for 6-phosphogluconate dehydrogenase (6-pgd) as a target for lung cancer therepy |
EP2861255B1 (en) | 2012-06-19 | 2019-10-09 | The Broad Institute, Inc. | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy |
US20150290193A1 (en) | 2012-10-12 | 2015-10-15 | Hi-Stem Ggmbh | Novel approaches for individualized therapy of pancreatic ductal adenocarcinoma |
WO2016144371A1 (en) | 2015-03-06 | 2016-09-15 | Mitchell Woods Pharmaceuticals, Inc. | Methods of treating cancer |
WO2016172332A1 (en) | 2015-04-22 | 2016-10-27 | The University Of North Carolina At Chapel Hill | A novel compound for the treatment of ewing sarcoma and high-throughput assays for identifying small molecules that modulate aberrant chromatin accessibility |
-
2017
- 2017-10-05 JP JP2019518463A patent/JP7239468B2/ja active Active
- 2017-10-05 US US16/340,069 patent/US11795510B2/en active Active
- 2017-10-05 AU AU2017340743A patent/AU2017340743A1/en active Pending
- 2017-10-05 WO PCT/US2017/055376 patent/WO2018067840A1/en unknown
- 2017-10-05 EP EP17859197.0A patent/EP3522924A4/en active Pending
-
2023
- 2023-08-01 US US18/229,064 patent/US20240011100A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Supplitt et al. | Current achievements and applications of transcriptomics in personalized cancer medicine | |
Heitzer et al. | Current and future perspectives of liquid biopsies in genomics-driven oncology | |
Wikman et al. | Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array | |
Vargas et al. | Biomarker development in the precision medicine era: lung cancer as a case study | |
Nie et al. | Long non‐coding RNA HOTAIR is an independent prognostic marker for nasopharyngeal carcinoma progression and survival | |
Kaczor‐Urbanowicz et al. | Emerging technologies for salivaomics in cancer detection | |
Schneider et al. | Global histone H4K20 trimethylation predicts cancer‐specific survival in patients with muscle‐invasive bladder cancer | |
Donepudi et al. | Breast cancer statistics and markers | |
Strand et al. | Prognostic DNA methylation markers for prostate cancer | |
Vieira et al. | Deregulated expression of selected histone methylases and demethylases in prostate carcinoma | |
Basnet et al. | The prognostic value of circulating cell-free DNA in colorectal cancer: a meta-analysis | |
Li et al. | Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer | |
Liu et al. | Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression | |
Wang et al. | Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non‐small cell lung cancer: A comparison of Ventana immunohistochemistry and fluorescence in situ hybridization | |
Rozevsky et al. | Quantification of mRNA expression using single-molecule nanopore sensing | |
Al-Khanbashi et al. | Tissue and serum miRNA profile in locally advanced breast cancer (LABC) in response to neo-adjuvant chemotherapy (NAC) treatment | |
JP2017507320A5 (ja) | ||
Zhang et al. | Circulating long non‐coding HOX transcript antisense intergenic ribonucleic acid in plasma as a potential biomarker for diagnosis of breast cancer | |
Ellinger et al. | Alterations of global histone H3K9 and H3K27 methylation levels in bladder cancer | |
Zhang et al. | Prevalence of ROS1 fusion in Chinese patients with non‐small cell lung cancer | |
Peskoe et al. | Differential long-term stability of microRNAs and RNU6B snRNA in 12–20 year old archived formalin-fixed paraffin-embedded specimens | |
Chiam et al. | Identification of microRNA biomarkers of response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma using next generation sequencing | |
Lin et al. | Elevated pre‑treatment levels of high sensitivity C‑reactive protein as a potential prognosticator in patients with colorectal cancer | |
Tong et al. | Multi-omics landscapes of colorectal cancer subtypes discriminated by an individualized prognostic signature for 5-fluorouracil-based chemotherapy | |
Ho et al. | Molecular diagnostic algorithm for epidermal growth factor receptor mutation detection in A sian lung adenocarcinomas: Comprehensive analyses of 445 Taiwanese patients with immunohistochemistry, PCR‐direct sequencing and S corpion/ARMS methods |